S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Options Trading Plan–Perfect For Beginners (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Options Trading Plan–Perfect For Beginners (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Forecast, Price & News

$11.11
-0.31 (-2.71%)
(As of 09/25/2023 ET)
Compare
Today's Range
$11.04
$11.55
50-Day Range
$11.11
$14.60
52-Week Range
$11.03
$23.00
Volume
185,729 shs
Average Volume
321,826 shs
Market Capitalization
$397.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.33

iTeos Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
227.0% Upside
$36.33 Price Target
Short Interest
Bearish
5.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of iTeos Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$5.69 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.26) to ($5.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

386th out of 962 stocks

Biological Products, Except Diagnostic Industry

58th out of 160 stocks


ITOS stock logo

About iTeos Therapeutics (NASDAQ:ITOS) Stock

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Price History

ITOS Stock News Headlines

iTeos to Participate in Upcoming Investor Conferences
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Why ITeos Therapeutics (ITOS) Stock Is Moving Higher
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)
iTeos Therapeutics: Trading Under Cash Value
iTeos Therapeutics (ITOS) Gets a Buy from H.C. Wainwright
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITOS Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.33
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+226.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$96.65 million
Pretax Margin
-31.00%

Debt

Sales & Book Value

Annual Sales
$267.63 million
Cash Flow
$2.62 per share
Book Value
$18.65 per share

Miscellaneous

Free Float
32,132,000
Market Cap
$397.87 million
Optionable
Not Optionable
Beta
1.20
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Michel Detheux Ph.D. (Age 57)
    Pres, CEO & Director
    Comp: $922.38k
  • Mr. Matthew A. Call M.B.A. (Age 50)
    Chief Operating Officer
    Comp: $638.55k
  • Mr. Matthew GallMr. Matthew Gall (Age 46)
    Chief Financial Officer
  • Dr. Yvonne McGrath Ph.D. (Age 49)
    Chief Scientific Officer
  • Mr. Ryan Baker
    Head of Investor Relations
  • Ms. Adi Osovsky
    VP & Head of Legal
  • Mr. Phillipe Brantegem
    Vice-Pres of HR













ITOS Stock - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings
or view top-rated stocks.

What is iTeos Therapeutics' stock price forecast for 2023?

3 brokers have issued 1 year price targets for iTeos Therapeutics' shares. Their ITOS share price forecasts range from $32.00 to $44.00. On average, they expect the company's share price to reach $36.33 in the next year. This suggests a possible upside of 226.7% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2023?

iTeos Therapeutics' stock was trading at $19.53 at the start of the year. Since then, ITOS stock has decreased by 43.1% and is now trading at $11.12.
View the best growth stocks for 2023 here
.

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,620,000 shares, an increase of 5.9% from the August 15th total of 1,530,000 shares. Based on an average daily volume of 425,900 shares, the short-interest ratio is currently 3.8 days. Approximately 5.5% of the company's stock are short sold.
View iTeos Therapeutics' Short Interest
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Tuesday, August, 8th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.07. iTeos Therapeutics had a net margin of 9.02% and a negative trailing twelve-month return on equity of 4.42%.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is iTeos Therapeutics' stock symbol?

iTeos Therapeutics trades on the NASDAQ under the ticker symbol "ITOS."

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.08%), State Street Corp (4.37%), Goldman Sachs Group Inc. (1.80%), Candriam S.C.A. (1.71%), 683 Capital Management LLC (1.63%) and Dimensional Fund Advisors LP (1.62%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends
.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iTeos Therapeutics' stock price today?

One share of ITOS stock can currently be purchased for approximately $11.12.

How much money does iTeos Therapeutics make?

iTeos Therapeutics (NASDAQ:ITOS) has a market capitalization of $397.87 million and generates $267.63 million in revenue each year. The company earns $96.65 million in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does iTeos Therapeutics have?

The company employs 125 workers across the globe.

How can I contact iTeos Therapeutics?

The official website for the company is www.iteostherapeutics.com. The company can be reached via phone at 339-217-0161 or via email at ir@iteostherapeutics.com.

This page (NASDAQ:ITOS) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -